文献速递功能神经外科

丘脑底核深部脑刺激对携带遗传风险因素/病因的帕金森病患者的影响研究

Investigation of the Impact of Deep Brain Stimulation of the Subthalamic Nucleus on Parkinson Disease Patients with Genetic Risk Factors/Causes.
PubMed 文献 · World Neurosurg · 2025-04-26

本研究比较了丘脑底核深部脑刺激(STN-DBS)在18例携带GBA、LRRK2或Parkin/PINK1/DJ1突变的帕金森病患者中的临床疗效,发现所有遗传背景患者均有显著时间依赖性改善,但LRRK2携带者2年时所需刺激能量更高,GBA携带者运动和生活质量改善较小。

要点

  • STN-DBS对携带GBA、LRRK2或Parkin/PINK1/DJ1突变的帕金森病患者均有显著时间依赖性改善。
  • LRRK2携带者2年时所需总电能量更高(时间×基因交互β=94.21,P=0.043)。
  • GBA携带者运动改善(vs LRRK2 β=-24.94,P=0.001;vs Parkin/PINK1/DJ1 β=-23.61,P=0.008)和PDQ-39改善(β=-22.67,P=0.018)较小。

核心结论

  • STN-DBS对携带GBA、LRRK2或Parkin/PINK1/DJ1突变的帕金森病患者均有获益,但LRRK2携带者可能随时间需要增加刺激,而GBA携带者运动和生活质量改善较小。

研究设计与样本

  • 比较18例携带GBA(n=3)、LRRK2(n=9)或Parkin/PINK1/DJ1(n=6)突变的帕金森病患者接受STN-DBS的结局。
  • 在基线、程控启动、术后6个月、1年和2年评估左旋多巴等效日剂量、MDS-UPDRS Part III、PDQ-39和总电能量。
  • 采用线性混合模型分析纵向和组间差异。

主要发现

  • 所有组均显示显著时间依赖性改善。
  • 左旋多巴等效日剂量在DBS后急剧下降(1年时最大降低:β=-577.33,P<0.001)。
  • MDS-UPDRS Part III评分在程控启动时改善(β=-35.00,P<0.001)并稳定2年。
  • PDQ-39评分从6个月起改善(β=-27.67,P<0.001)。
  • 总电能量逐渐增加,LRRK2携带者2年时需要更高刺激(时间×基因交互:β=94.21,P=0.043)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The impact of deep brain stimulation of the subthalamic nucleus (STN-DBS) on patients with Parkinson disease (PD) with different genetic risk factors/causes remains uncertain. This study aimed to compare the clinical efficacy of STN-DBS in these patients. METHODS: This study compared STN-DBS outcomes in 18 PD patients with mutations in glucosylceramidase beta (GBA) (n = 3), leucine-rich repeat kinase 2 (LRRK2) (n = 9), or Parkin RBR E3 ubiquitin ligase/PTEN-induced kinase 1/DJ1 (n = 6). Clinical measures-levodopa equivalent daily dose, Movement Disorder Society Unified-Parkinson Disease Rating Scale Part III, Parkinson's Disease Questionnaire-39 (PDQ-39), and total electrical energy delivered-were assessed at baseline, programming initiation, 6 months, 1 year, and 2 years postsurgery. Linear mixed models analyzed longitudinal and intergroup differences. RESULTS: All groups showed significant time-dependent improvements. Levodopa equivalent daily dose dropped sharply post-DBS (maximal reduction at 1 year: β = -577.33, P < 0.001). Movement Disorder Society Unified-Parkinson Disease Rating Scale Part III scores improved by programming initiation (β = -35.00, P < 0.001) and remained stable for 2 years. PDQ-39 scores improved from 6 months onward (β = -27.67, P < 0.001). Total electrical energy delivered increased gradually, with LRRK2 carriers requiring higher stimulation by 2 years (time × gene interaction: β = 94.21, P = 0.043). Main effects revealed GBA carriers had smaller motor improvements (vs. LRRK2: β = -24.94, P = 0.001; vs. Parkin RBR E3 ubiquitin ligase/PTEN-induced kinase 1/DJ1: β = -23.61, P = 0.008) and lesser PDQ-39 gains (β = -22.67, P = 0.018). CONCLUSIONS: STN-DBS demonstrated benefits for patients with PD across all genetic backgrounds, but LRRK2 carriers may require increasing stimulation over time, while GBA carriers show reduced motor and quality-of-life improvements.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wu S, Cen Z, Zheng X, et al. Investigation of the Impact of Deep Brain Stimulation of the Subthalamic Nucleus on Parkinson Disease Patients with Genetic Risk Factors/Causes. World Neurosurg. 2025. PMID: 40294793. doi:10.1016/j.wneu.2025.124021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。